Healthy Adult Male
Conditions
Keywords
phrase 1
Brief summary
This study is a randomized, double-Blind, parallel-controlled, single-dose pharmacokinetic, safety, and immunogenicity comparative study of EnliTuo® before and after technology change in healthy male volunteers.
Interventions
BIOLOGICALNew technology Enlituo
250 mg/m\^2, single intravenous drip
BIOLOGICALApproved technology Enlituo
250 mg/m\^2, single intravenous drip
Sponsors
Taizhou Mabtech Pharmaceutical Co.,Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy males aged ≥ 18 years and ≤ 45 years on the day of signing the informed consent form; * At screening, body weight ≥ 50 kg and ≤ 80 kg, with a Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive of boundary values); * Capable of understanding the study, including its purpose, research procedures, potential risks, etc., and able to communicate well with researchers and complete the study in accordance with the study requirements; * Voluntarily sign the informed consent form.
Exclusion criteria
* Subjects with any abnormally clinically significant findings in comprehensive examinations (vital signs, physical examination, electrocardiogram, chest X-ray, abdominal ultrasound, blood routine, urine routine, blood biochemistry, coagulation, etc.) as judged by the investigator; * Subjects with a history of major diseases in the cardiovascular, endocrine, nervous, digestive, respiratory, genitourinary, hematological, immune, or mental systems, or currently suffering from any disease in the above systems; * Subjects with a known or suspected history of keratitis, ulcerative keratitis, conjunctivitis, blepharitis, or severe dry eye; * Subjects with hereditary bleeding tendency, coagulation dysfunction, or a history of thrombotic or hemorrhagic diseases; * Subjects with active infections requiring systemic treatment; * Subjects positive for any of HBV surface antigen, HCV antibody, HIV antibody, or Treponema pallidum antibody; * Subjects with a history of malignant tumors within the past 5 years, except for completely resected in-situ cutaneous basal cell carcinoma or squamous cell carcinoma; * Subjects who have undergone surgical operations within 4 weeks before screening, or plan to undergo surgery during the trial period; * Subjects who have used any prescription drugs, over-the-counter drugs, traditional Chinese medicines, proprietary Chinese medicines, health supplements, etc., within 4 weeks before screening, or whose use of the above substances has not exceeded 5 half-lives (whichever is longer); * Subjects who have used any biological products or received any vaccines within 12 weeks before screening, or plan to receive any vaccines during the study period; * Subjects currently enrolled in other clinical studies of drugs or medical devices, or whose time since the end of the last enrolled clinical study is less than 12 weeks, or whose time since the last trial drug administration has not exceeded 5 half-lives (whichever is longer); * Subjects positive for anti-drug antibodies against anti-epidermal growth factor receptor antibodies; * Subjects with substance abuse, or who have used soft drugs within 3 months before screening or hard drugs within 1 year before screening; or who consume excessive tea, coffee, and/or caffeinated beverages daily (more than 8 cups, 1 cup = 250 mL); or who have a positive urine drug screen; * Subjects with alcoholism, or whose weekly alcohol consumption exceeds 14 units within 3 months before screening (1 unit = 17.7 mL ethanol, i.e., 1 unit = 357 mL of beer with 5% alcohol content, 43 mL of liquor with 40% alcohol content, or 147 mL of wine with 12% alcohol content); or who have a positive alcohol breath test; and those who cannot cooperate with alcohol prohibition during the study; * Subjects who smoked more than 10 cigarettes per day on average within 6 months before screening; * Subjects who engaged in strenuous activities within 72 hours before drug administration, or cannot avoid strenuous activities during the study; or have other physiological or pathological conditions that may affect the absorption, distribution, metabolism, or excretion of the study drug; * Subjects who have donated blood (including component blood) or lost more than 400 mL of blood, or received blood transfusions within 3 months before screening; or donated blood (including component blood) or lost more than 200 mL of blood within 1 month before screening; * Subjects with a known history of allergy to the active ingredient or any excipient of the study drug, or to other biological products; or with a history of atopic allergic diseases (e.g., asthma, urticaria, eczematous dermatitis, etc.); or with allergic diathesis; * Subjects who cannot tolerate venipuncture or have a history of fainting due to needle or blood; * Subjects with special dietary requirements who cannot accept the diet provided by the clinical trial center; * Subjects who cannot take effective contraceptive measures or plan to donate sperm within 3 months after the administration of the study drug; * Other conditions deemed by the investigator to make the subject unsuitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC0-∞ | From enrollment to the end of treatment at 28 days | Area under the concentration time curve extrapolated to infinity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC0-t | From enrollment to the end of treatment at 28 days | Area under the concentration time curve from time zero to the last measurable time point. |
| Cmax | From enrollment to the end of treatment at 28 days | Peak concentration. |
| Tmax | From enrollment to the end of treatment at 28 days | time to peak |
| t1/2 | From enrollment to the end of treatment at 28 days | half-life |
| λz | From enrollment to the end of treatment at 28 days | Terminal Elimination Rate Constant |
| CL | From enrollment to the end of treatment at 28 days | clearance |
| Vd | From enrollment to the end of treatment at 28 days | volume of distribution |
| Immunogenicity | From enrollment to the end of treatment at 28 days | Anti-drug antibody positive rate |
| Adverse Event | From enrollment to the end of treatment at 6 months | Incidence and Severity of Adverse Events |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORJingying Jia, PhD
Shanghai Xuhui Central Hospital
Outcome results
None listed